CRDF SEC Filings: 8-K, 10-Q, S-3 & 424B – Cardiff Oncology

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 24, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 29, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer

Oct 27, 2026

8-K

Cardiff Oncology, Inc. Special Meeting Results on Authorized Shares Amendment

Oct 22, 2026

8-K

Cardiff Oncology and Nerviano Medical Sciences Amend 2017 Exclusive License Agreement and Resolve All Litigation

Sep 14, 2026

8-K

Cardiff Oncology Reports Q2 2026 Results and Progress Toward Phase 3 Registrational Trial

Aug 11, 2026

8-K

Cardiff Oncology Announces $10 Million Registered Direct Offering

Jul 16, 2026

8-K

Cardiff Oncology, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 11, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Jul 16, 2026

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Dec 11, 2024

424B5

SHELF OFFERING | Shares amount: 2,411,575 | Share price: $6.22 | Offering amount: $14,999,997.00

Nov 18, 2021

424B5

6,500,000 Shares of Common Stock

Sep 30, 2020

424B5

_______ Shares of Common Stock

Sep 29, 2020

424B3

6,243,734 Shares

Jul 13, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8

Cardiff Oncology, Inc. Grants Stock Options to Josh Muntner

Jul 21, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 28, 2025

S-3/A

SHARE RESALE REGISTRATION | Offering amount: $400,000,000

May 8, 2025

S-3

Form S-3 - Registration statement under Securities Act of 1933

Feb 27, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 1, 2024

S-8

Registration

Mar 27, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Aug 26, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Aug 26, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Aug 14, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Alland Leila (Reporting)

Oct 27, 2026

SCHEDULE 13G/A

BlackRock, Inc. (Filed by)

Jul 27, 2026

PACE GARY W (Reporting)

Jul 16, 2026

Mohindru Mani (Reporting)

Jul 16, 2026

Mohindru Mani (Reporting)

Jun 22, 2026

PACE GARY W (Reporting)

Jun 22, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 14, 2025

CORRESP

Form CORRESP - Correspondence

May 12, 2025

LETTER

Form UPLOAD - SEC-generated letter

Mar 6, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 26, 2022

CORRESP

Form CORRESP - Correspondence

Apr 21, 2022

LETTER

Form UPLOAD - SEC-generated letter

Apr 14, 2022

Cardiff Oncology, Inc. CRDF · SEC Filings